|
業務類別
|
Biotechnology |
|
業務概覽
|
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid. |
| 公司地址
| 535 W 24th Street, 5th Floor, New York, NY, USA, 10011 |
| 電話號碼
| +1 855 508-3568 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.neurogene.com |
| 員工數量
| 107 |
| Dr. Stuart Cobb, PhD |
Chief Scientific Officer |
-- |
25/04/2025 |
| Ms. Christine Mikail Cvijic, J.D. |
President, Chief Financial Officer and Principal Accounting Officer |
美元 515.00K |
25/04/2025 |
| Dr. Rachel McMinn, PhD |
Executive Chairman of the Board and Chief Executive Officer |
美元 595.00K |
25/04/2025 |
| Dr. Julie Jordan, M.D. |
Chief Medical Officer |
美元 460.00K |
25/04/2025 |
|
|
| Dr. Sarah B. Noonberg, M.D.,PhD |
Independent Director |
25/04/2025 |
| Dr. Robert A. Baffi,PhD |
Independent Director |
25/04/2025 |
| Dr. Cory Freedland, PhD |
Independent Director |
25/04/2025 |
| Dr. Rachel McMinn, PhD |
Executive Chairman of the Board and Chief Executive Officer |
25/04/2025 |
| Mr. Rohan Palekar |
Independent Director |
25/04/2025 |
| Mr. Robert Keith Woods |
Independent Director |
25/04/2025 |
|
|
|
|
